• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    6/19/24 1:35:26 PM ET
    $BMY
    $CYH
    $DHR
    $ELV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $BMY alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    CYH CALL SWEEP BEARISH 07/19/24 $3.00 $57.8K 3.6K 2.1K
    UNH PUT SWEEP BEARISH 01/16/26 $490.00 $129.6K 218 901
    LLY CALL TRADE NEUTRAL 08/16/24 $900.00 $82.3K 1.0K 263
    BMY PUT TRADE BEARISH 08/16/24 $45.00 $25.4K 3.6K 245
    SRPT CALL TRADE NEUTRAL 06/21/24 $117.00 $59.8K 1 87
    VEEV PUT TRADE BULLISH 01/17/25 $210.00 $118.3K 156 35
    ELV CALL SWEEP BULLISH 06/21/24 $530.00 $30.2K 420 28
    TDOC PUT SWEEP BEARISH 01/17/25 $15.00 $26.4K 1.9K 26
    DHR PUT SWEEP BULLISH 01/17/25 $260.00 $35.2K 654 20
    UTHR CALL SWEEP BEARISH 08/16/24 $320.00 $55.6K 25 5

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For CYH (NYSE:CYH), we notice a call option sweep that happens to be bearish, expiring in 30 day(s) on July 19, 2024. This event was a transfer of 888 contract(s) at a $3.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $57.8K, with a price of $65.0 per contract. There were 3620 open contracts at this strike prior to today, and today 2114 contract(s) were bought and sold.

    • Regarding UNH (NYSE:UNH), we observe a put option sweep with bearish sentiment. It expires in 576 day(s) on January 16, 2026. Parties traded 27 contract(s) at a $490.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $129.6K, with a price of $4800.0 per contract. There were 218 open contracts at this strike prior to today, and today 901 contract(s) were bought and sold.

    • Regarding LLY (NYSE:LLY), we observe a call option trade with neutral sentiment. It expires in 58 day(s) on August 16, 2024. Parties traded 20 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $82.3K, with a price of $4119.0 per contract. There were 1066 open contracts at this strike prior to today, and today 263 contract(s) were bought and sold.

    • For BMY (NYSE:BMY), we notice a put option trade that happens to be bearish, expiring in 58 day(s) on August 16, 2024. This event was a transfer of 50 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $510.0 per contract. There were 3652 open contracts at this strike prior to today, and today 245 contract(s) were bought and sold.

    • Regarding SRPT (NASDAQ:SRPT), we observe a call option trade with neutral sentiment. It expires in 2 day(s) on June 21, 2024. Parties traded 41 contract(s) at a $117.00 strike. The total cost received by the writing party (or parties) was $59.8K, with a price of $1460.0 per contract. There were 1 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold.

    • Regarding VEEV (NYSE:VEEV), we observe a put option trade with bullish sentiment. It expires in 212 day(s) on January 17, 2025. Parties traded 35 contract(s) at a $210.00 strike. The total cost received by the writing party (or parties) was $118.3K, with a price of $3380.0 per contract. There were 156 open contracts at this strike prior to today, and today 35 contract(s) were bought and sold.

    • Regarding ELV (NYSE:ELV), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on June 21, 2024. Parties traded 100 contract(s) at a $530.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $30.2K, with a price of $304.0 per contract. There were 420 open contracts at this strike prior to today, and today 28 contract(s) were bought and sold.

    • Regarding TDOC (NYSE:TDOC), we observe a put option sweep with bearish sentiment. It expires in 212 day(s) on January 17, 2025. Parties traded 50 contract(s) at a $15.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $529.0 per contract. There were 1982 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold.

    • Regarding DHR (NYSE:DHR), we observe a put option sweep with bullish sentiment. It expires in 212 day(s) on January 17, 2025. Parties traded 22 contract(s) at a $260.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $35.2K, with a price of $1600.0 per contract. There were 654 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold.

    • Regarding UTHR (NASDAQ:UTHR), we observe a call option sweep with bearish sentiment. It expires in 58 day(s) on August 16, 2024. Parties traded 48 contract(s) at a $320.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.6K, with a price of $1160.0 per contract. There were 25 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMY
    $CYH
    $DHR
    $ELV

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    Veeva Systems Inc.
    $VEEV
    2/17/2026$205.00Underweight → Equal-Weight
    Morgan Stanley
    Elevance Health Inc.
    $ELV
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Veeva Systems Inc.
    $VEEV
    1/13/2026$215.00Sell
    Goldman
    Veeva Systems Inc.
    $VEEV
    1/8/2026Hold → Buy
    Truist
    Elevance Health Inc.
    $ELV
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $BMY
    $CYH
    $DHR
    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Bristol-Myers with a new price target

    Barclays initiated coverage of Bristol-Myers with a rating of Overweight and set a new price target of $75.00

    2/20/26 8:24:06 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veeva Systems upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Veeva Systems from Underweight to Equal-Weight and set a new price target of $205.00

    2/17/26 8:05:30 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $BMY
    $CYH
    $DHR
    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from 2:30 to 3:00 p.m. EST, at the TD Cowen 46th Annual Health Care Conference in Boston. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creati

    2/23/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

    Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints Bristol Myers Squibb (NYSE:BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in adults with Alpha (α)-Thalassemia. The non‑transfusion‑dependent (NTD) and transfusion‑dependent (TD) cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating a statistically significant and clinically meaningful increase in hemoglobin levels in NTD patients with α‑thalassemia, and a statistically significant and clinically meaning

    2/23/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    $BMY
    $CYH
    $DHR
    $ELV
    SEC Filings

    View All

    SEC Form 10-K filed by Community Health Systems Inc.

    10-K - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Filer)

    2/19/26 4:32:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Teladoc Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Teladoc Health, Inc. (0001477449) (Filer)

    2/18/26 4:30:43 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Community Health Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Filer)

    2/18/26 4:30:34 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $BMY
    $CYH
    $DHR
    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Milosevich Gregory M exercised 1,320 shares at a strike of $58.59 and sold $274,575 worth of shares (1,320 units at $208.01) (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    2/20/26 5:00:11 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    EVP & GENERAL COUNSEL Mahon Paul A exercised 8,300 shares at a strike of $146.03 and sold $3,953,588 worth of shares (8,300 units at $476.34) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    2/19/26 4:31:47 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief People Officer Dozier Eric gifted 481 shares, decreasing direct ownership by 3% to 14,455 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/19/26 4:18:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $CYH
    $DHR
    $ELV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $CYH
    $DHR
    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Paulus Kenneth H bought $69,400 worth of shares (10,000 units at $6.94) (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    11/17/25 4:05:05 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Director Devore Susan D. bought $374,580 worth of shares (1,200 units at $312.15), increasing direct ownership by 52% to 3,502 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/21/25 4:20:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $CYH
    $DHR
    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122174254/en/Kevin Tracey was recently elected to United Therapeutics' Board of Directors. Dr. Tracey is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Executive Vice Pres

    1/22/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $CYH
    $DHR
    $ELV
    Financials

    Live finance-specific insights

    View All

    Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors

    NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Michael Smith to its board of directors. With more than three decades of leadership experience in financial management and strategic transformation, Mr. Smith brings a deep understanding of long-term business sustainability within highly regulated, global markets. He joins the board following the previously announced retirements of Eric Evans and Thomas McKinley and will serve on the board's audit and nominating and corporate governance committees. "Michael's experience leading enterprise transformations makes him a strong addition to the Board," sa

    2/18/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Community Health Systems, Inc. Announces Fourth Quarter and Year Ended December 31, 2025 Results

    Community Health Systems, Inc. (NYSE:CYH) (the "Company") today announced financial and operating results for the three months and year ended December 31, 2025. The following highlights the financial and operating results for the three months ended December 31, 2025. Net operating revenues totaled $3.106 billion. Net income attributable to Community Health Systems, Inc. stockholders was $110 million, or $0.81 per share (diluted), compared to net loss of $(70) million, or $(0.53) per share (diluted), for the same period in 2024. Excluding the adjusting items as presented in the table in footnote (e) on page 15, net income attributable to Community Health Systems, Inc. stockholders wa

    2/18/26 4:15:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BMY
    $CYH
    $DHR
    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Community Health Systems Inc.

    SC 13G/A - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Subject)

    11/14/24 5:52:10 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Community Health Systems Inc.

    SC 13G/A - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Subject)

    11/14/24 4:11:11 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care